Alternatives to Scinus Group

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing ultrasound-mediated nonviral genetic medicines.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Developing novel male contraceptives.

Developing a new histotripsy therapeutic platform for cancer treatment.

Platform designed to cut cell and gene therapy production costs.

Elevating uterine health through innovative biomaterial therapies.

AI-enabled technology for cell biology research and biopharma development.

Develops multimodal hemoadsorption therapeutic devices for sepsis and septic shock.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Global supplier of life science research tools, including antibodies, reagents, and assays.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A vertically-integrated procurement platform for the life sciences industry.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Developing novel immunotherapies and diagnostics for cancer.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Developing gene editing therapies to lower cholesterol.

AI-powered knowledge discovery for life sciences.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Revolutionizing genomic analysis with innovative sequencing technology.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A full-stack spatial biology company.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing non-invasive ultrasound neuromodulation therapies for chronic immune-mediated diseases and inflammatory disorders.

Unlocking industrial-scale RNA-seq for primary drug screening and toxicology.

Developing magnetic cell delivery platform for advanced therapies.

Developing first-in-class oral therapy for BK polyomavirus infections.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing epigenetic reprogramming drugs for age restoration.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.